InvestorsHub Logo
Followers 15
Posts 1122
Boards Moderated 0
Alias Born 07/28/2014

Re: None

Tuesday, 07/10/2018 1:39:18 PM

Tuesday, July 10, 2018 1:39:18 PM

Post# of 536
The final patient has been enrolled and dosed in the third Phase 3 study (FX2017-22) investigating FMX101, the Company’s minocycline foam 4%, in patients with moderate-to severe acne.
(May 08, 2018 17:04 ET)

* Top-line results are expected in the third quarter of 2018.